Clinical trial · Interventional
Vactosertib and Durvalumab in Gastric Cancer
Vactosertib in Combination With Durvalumab (MEDI4736) in Patients With Gastric Cancer
NCT04893252CI-TRIAL-00062398unknownPhase 2ClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
This trial will test the efficacy and safety of durvalumab in combination with vactosertib in patients with metastatic gastric cancers who failed ≥ 2 lines of chemotherapy
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Stomach Neoplasm | Gastric Neoplasm | ALIAS | 0.90 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| durvalumab and vactosertib | Drug | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- type
- EXPERIMENTAL
- label
- vactosertib in combination with durvalumab
- description
- single arm study
- interventionNames
- Drug: durvalumab and vactosertib
Primary outcomes (1)
- measure
- Objective response rate
- timeFrame
- Every 8 weeks from the date of the first dose until the date of progression, assessed up to 1 year
- description
- Objective response rate in 55 participants according to RECIST v1.1
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Have histologically- or cytologically-confirmed diagnosis of metastatic gastric adenocarcinoma in the stomach and gastroesophageal junction that are refractory to at least two lines of treatment. * Have a performance status of 0-1 on the ECOG Performance Scale. * Have measurable disease at least one investigator-assessed measurable disease per RECIST v1.1 * Have adequate organ functions Exclusion Criteria: * Prior ALK5 inhibitor treatment * Current or prior use of immunosuppressive medication within 14 days before the first dose of study drugs * Patients weighing \<30kg
References
Publications (0)
Data not yet available
No reference posted for this study.